Femara 2.5mg Tablet (Letrozole)

Femara 2.5mg Tablet contains letrozole, an oral aromatase inhibitor used as endocrine therapy for hormone-receptor-positive breast cancer, mainly in postmenopausal women. Aromatase is an enzyme involved in producing estrogen after menopause. By inhibiting this enzyme, the letrozole 2.5mg tablet lowers estrogen levels and can slow the growth of breast cancers that depend on estrogen signaling.

Letrozole tablets may be used after surgery, as extended adjuvant treatment, before surgery in selected patients, or for advanced/metastatic disease depending on the clinical setting. Femara 2.5mg Tablet is a prescription medicine and should be used under the supervision of an oncologist. Long-term treatment can affect bone density and cholesterol, so appropriate monitoring and supportive care are important.

Letrozole tablets are used for hormone-receptor-positive breast cancer in postmenopausal patients. It may be prescribed as adjuvant endocrine therapy after surgery, including after prior tamoxifen; as extended adjuvant therapy; for locally advanced or metastatic hormone-sensitive breast cancer; and, in selected patients, before surgery to reduce tumor size.

Treatment choice depends on menopausal status, hormone-receptor results, cancer stage, previous endocrine therapy, recurrence risk, and tolerance. Letrozole 2.5mg tablet is not a general treatment for every type of breast cancer. Premenopausal patients may require ovarian suppression if an aromatase inhibitor is used as part of their treatment strategy.

Letrozole 2.5mg tablet is a non-steroidal aromatase inhibitor. In postmenopausal patients, aromatase converts adrenal androgen into estrogen in peripheral tissues. Letrozole tablets inhibit this conversion and markedly lower circulating estrogen levels. Hormone-receptor-positive breast cancers may rely on estrogen signaling for growth, so reducing estrogen can slow tumor-cell proliferation and reduce recurrence risk. The same reduction in estrogen contributes to adverse effects such as hot flushes, joint symptoms, and loss of bone mineral density.

Evidence context: The studies below are pivotal or widely cited evidence supporting the letrozole 2.5mg tablet in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Femara 2.5mg tablets may cause side effects, and their frequency varies by indication, dose, combination regimen, and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

Common side effects

• Hot flushes
• Joint or muscle pain
• Fatigue
• Increased sweating
• Headache
• Nausea
• Bone loss / osteoporosis over time
• Increased cholesterol

Serious side effects

• Osteoporosis-related fractures
• Cardiovascular events in susceptible patients
• Severe liver or allergic reactions (rare)

The standard labeled dose for letrozole 2.5mg tablets in breast cancer is 2.5 mg orally once daily, with or without food. Treatment duration depends on the setting: adjuvant and extended-adjuvant therapy may continue for years, while advanced disease treatment generally continues while benefit persists and toxicity is acceptable. Pre-menopausal patients require specialist assessment and, when appropriate, ovarian suppression if an aromatase inhibitor is used.

Administration guidance: Take the Femara 2.5mg tablet exactly as prescribed, usually once daily. Swallow the tablet with water and take it at approximately the same time each day. It can generally be taken with or without food. Continue treatment for the duration recommended by your oncologist, which may be several years in adjuvant breast cancer therapy. Do not stop because you feel well; endocrine therapy is intended to reduce recurrence risk or control hormone-sensitive disease over time. Your doctor may monitor bone mineral density, cholesterol, and other health factors during long-term therapy. Calcium, vitamin D, or bone-protective treatment may be recommended for some patients based on individual risk.

Take a missed dose when remembered unless it is close to the next dose. Do not take two doses together. Resume the regular once-daily schedule.

Assess bone health and fracture risk at baseline and periodically during long-term therapy. Monitor cholesterol according to clinical risk. Consider liver function and cardiovascular risk factors. Evaluate persistent musculoskeletal symptoms because they can affect adherence.​

Practical monitoring checklist

• Bone mineral density / fracture risk
• Lipids and cardiovascular risk factors as clinically indicated
  

• FDA/EMA Femara (letrozole) Prescribing Information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf​
• NCCN Clinical Practice Guidelines in Oncology: Breast Cancer.https://www.nccn.org/guidelines/guidelines-detail?id=1419.
• National library for medicine. Letrozole for female infertility.https://pmc.ncbi.nlm.nih.gov/articles/PMC8245002/​
• ScienceDirect. Latrozole.https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/letrozole​
• International journal of reproduction, contraception, obstetrics and Gynecology A comparative study of Latrozole..https://www.ijrcog.org/index.php/ijrcog/article/view/14325